SANUWAVE Health Business Summary

SANUWAVE Health, Inc. (SNWV) operates as a commercial-stage medical technology company specializing in non-invasive, energy-based regenerative medicine. The company utilizes a high-margin "razor/razor blade" business model, generating revenue through the sale and leasing of durable shockwave and ultrasound generators—primarily the UltraMIST and dermaPACE systems—complemented by recurring sales of single-use, disposable applicators required for each patient treatment. Its primary business segments are focused on advanced wound care, specifically targeting chronic conditions like diabetic foot ulcers and pressure sores, where its technology serves as a cost-effective alternative to expensive skin substitutes. Positioned as a high-growth disruptor in the medical equipment space, SANUWAVE competes directly with MiMedx Group (MDXG), Bioventus (BVS), and Butterfly Network (BFLY), distinguishing itself through its patented Pulsed Acoustic Cellular Expression (PACE) technology that stimulates biological healing without the need for biological grafts. Originally founded in 2004, the company underwent a significant leadership overhaul in recent years led by Chairman and CEO Morgan C. Frank, a capital markets veteran and principal at Manchester Management, the company's largest shareholder. The current executive team includes Chief Technology Officer Christopher Cook, who joined in January 2026 with 30 years of experience in energy-based medical physics, Chief Operating Officer Daniel Coyle, an engineering specialist appointed in late 2025, and Chief Financial Officer Peter Sorensen, formerly of Endogenex and LivaNova. The company's strategic direction is further supported by a board featuring industry experts like James Tyler, a former COO of Healogics, and Jeffrey Blizard, a former sales leader at Abiomed. Notable institutional backing includes significant positions held by Opaleye Management, Solas Capital Management, and Vanguard Group, reflecting a recapitalized structure following the company's 2025 uplisting to the NASDAQ Global Market.